GKIM
NDRM

GW&K Investment Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

GW&K Investment Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-97,120
Closed -$3.78M – 280
2017
Q3 		$3.78M Sell
97,120
-680
-0.7% -$25K 0.06% 199
2017
Q2 		$2.92M Buy
+97,800
New +$2.53M 0.05% 198

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

GW&K Investment Management's NDRM Position: Q4 2017 in Review

GW&K Investment Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 97,120 shares — an estimated $3.78M sold.

GW&K Investment Management first reported a position in NDRM in Q2 2017 and held it in 2 quarters. The position peaked at $3.78M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • GW&K Investment Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • GW&K Investment Management sold 97,120 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $3.78M.
  • GW&K Investment Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2017 and held it in 2 quarters.
  • GW&K Investment Management's NeuroDerm Ltd. Ordinary Shares position peaked at $3.78M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on GW&K Investment Management's 13F filing for Q4 2017, filed 19 Jan 2018.